Intercept Pharmaceuticals
A biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases. Learn more
Launch date
Employees
Market cap
-
Enterprise valuation
AUD858m (Public information from 2024)
Share price
$19 ICPT
New York City New York (HQ)
Authorizing premium user...